PMID- 20511731
OWN - NLM
STAT- MEDLINE
DCOM- 20100915
LR  - 20181201
IS  - 1538-1145 (Electronic)
IS  - 1527-4160 (Linking)
VI  - 16
IP  - 2
DP  - 2010 Mar
TI  - Impact of smoking cessation on psychiatric inpatients treated with clozapine or 
      olanzapine.
PG  - 75-81
LID - 10.1097/01.pra.0000369968.80155.3f [doi]
AB  - INTRODUCTION: The prevalence of smoking is high in persons with serious mental 
      illness (SMI) despite associated health risks. Persons with SMI die on average 25 
      years earlier than the general population and an increased focus on wellness, 
      including smoking cessation, has been a goal of federal, state, and municipal 
      governments. OBJECTIVES: The primary objective of this study was to evaluate the 
      effects of smoking cessation on symptom severity in psychiatric inpatients at a 
      New York State psychiatric facility 1 year after a smoke-free policy had been 
      implemented. The secondary objective of this study was to evaluate 
      cardiometabolic risk factors. METHODS: A retrospective chart review of 26 adult 
      psychiatric inpatients receiving either clozapine, olanzapine, or both at any 
      time between January 2006 and December 2007 was conducted. In addition to Brief 
      Psychiatric Rating Scale (BPRS) scores and cardiometabolic measures (body weight, 
      body mass index [BMI], and blood pressures before and after implementation of the 
      smoke-free policy), other information collected included age, gender, diagnosis, 
      the frequency of psychiatric medications used on an as-needed (p.r.n.) basis, 
      immediate-need (stat) medication use, medication dosing, number of psychiatric 
      emergencies, Global Assessment of Functioning (GAF) scores, privilege status, and 
      time in special observation. Patients were compared on their own pre- and 
      post-smoking cessation parameters and data were analyzed using a dependent t-test 
      with p < 0.01 chosen as indicating significance. RESULTS: Data analysis revealed 
      a small but statistically significant decrease in GAF scores (p < 0.01), but no 
      other significant difference between values pre- and post-smoking cessation. 
      CONCLUSION: Analysis demonstrated no change in psychiatric symptomatology or 
      cardiometabolic factors 1 year post-smoking cessation in individuals with 
      schizophrenia taking clozapine, olanzapine, or both. Further investigation is 
      needed before concluding that smoking cessation has no impact on symptoms or on 
      cardiometabolic risk factors. Despite a slight but statistically significant 
      worsening in GAF scores, the health benefits of smoking cessation should continue 
      to form the basis of encouraging smoking cessation in persons with SMI while 
      longer term and methodologically more rigorous assessments on psychiatric and 
      general health status are undertaken.
FAU - Cole, Miranda L
AU  - Cole ML
AD  - New York State Office of Mental Health, Buffalo Psychiatric Center and State 
      University of New York, University at Buffalo School of Pharmacy and 
      Pharmaceutical Sciences, USA. Miranda.cole@omh.state.ny.us
FAU - Trigoboff, Eileen
AU  - Trigoboff E
FAU - Demler, Tammie Lee
AU  - Demler TL
FAU - Opler, Lewis A
AU  - Opler LA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Psychiatr Pract
JT  - Journal of psychiatric practice
JID - 100901141
RN  - 0 (Antipsychotic Agents)
RN  - 12794-10-4 (Benzodiazepines)
RN  - J60AR2IKIC (Clozapine)
RN  - N7U69T4SZR (Olanzapine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antipsychotic Agents/*administration & dosage
MH  - Benzodiazepines/*administration & dosage
MH  - Blood Pressure
MH  - Body Weight/drug effects
MH  - Brief Psychiatric Rating Scale
MH  - Clozapine/*administration & dosage
MH  - Comorbidity
MH  - Cross-Sectional Studies
MH  - Female
MH  - *Hospitalization
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Olanzapine
MH  - Retrospective Studies
MH  - Schizophrenia/diagnosis/*drug therapy/epidemiology
MH  - *Schizophrenic Psychology
MH  - Smoking/adverse effects/epidemiology
MH  - Smoking Cessation/*psychology
EDAT- 2010/06/01 06:00
MHDA- 2010/09/16 06:00
CRDT- 2010/06/01 06:00
PHST- 2010/06/01 06:00 [entrez]
PHST- 2010/06/01 06:00 [pubmed]
PHST- 2010/09/16 06:00 [medline]
AID - 00131746-201003000-00002 [pii]
AID - 10.1097/01.pra.0000369968.80155.3f [doi]
PST - ppublish
SO  - J Psychiatr Pract. 2010 Mar;16(2):75-81. doi: 10.1097/01.pra.0000369968.80155.3f.